Intensive Blood Pressure Control and Low-Cost Diuretic Significantly Reduce Secondary Stroke Risk
Driving systolic blood pressure below 120 mm Hg reduces major cardiovascular events by 21 percent in stroke survivors. A concurrent trial demonstrated that adding the inexpensive diuretic spironolactone helps patients successfully achieve these aggressive new targets.
Share this story
The critical window for preventing a second stroke opens the moment a patient leaves the hospital, and the outcome largely depends on a single, measurable metric. Strict blood pressure control is the most effective defense against recurrence, yet achieving the necessary targets often falls short in everyday clinical practice.[4]
Neurologists and primary care physicians have debated exactly how low a stroke survivor's blood pressure should go. Concerns about reducing cerebral perfusion have historically made some clinicians hesitant to push systolic targets below the standard 140 mm Hg.[4]
New data presented at the 2026 American Heart Association Scientific Sessions in Chicago fundamentally shifts that calculus. The OPTIMAL-STROKE trial demonstrated that driving systolic blood pressure below 120 mm Hg significantly reduces the risk of subsequent cardiovascular events.[2][4]
Simultaneously, a separate study known as the REDUCE trial offered a practical, accessible solution for reaching those aggressive new targets. Researchers found that adding spironolactone, an inexpensive and widely available diuretic, effectively lowered difficult-to-control blood pressure in stroke survivors.[1]
The case for aggressive targets
The OPTIMAL-STROKE trial, published concurrently in the New England Journal of Medicine, enrolled 4,368 patients across 30 centers in Brazil. Participants had previously experienced an ischemic stroke or a transient ischemic attack and were randomized to either standard or intensive blood pressure management.[3][5]
Over a median follow-up of nearly four years, the intensive treatment group aimed for a systolic target below 120 mm Hg. The standard care group maintained the conventional goal of keeping their systolic pressure below 140 mm Hg.[4][5]
The results provided a clear mandate for tighter control. Major adverse cardiovascular events occurred in 10.9 percent of patients in the intensive group, compared to 13.5 percent of those receiving standard care.[3][5]
"Our study shows that for many people who have already experienced an ischemic stroke or TIA, aiming for a systolic blood pressure below 120 mm Hg can provide additional cardiovascular protection," said Dr. Gisele Sampaio Silva, the study's principal investigator.[2][4]
The intensive strategy specifically reduced the rate of recurrent strokes, which fell from 6.4 percent in the standard group to 4.7 percent. This 27 percent relative reduction in stroke recurrence translates to a substantial number of prevented events across a broader population.[2][4]
A low-cost tool for a difficult task
While the OPTIMAL-STROKE trial established the destination, the REDUCE trial illuminated a highly effective path to get there. Reaching a systolic pressure below 120 mm Hg is notoriously difficult, often requiring a complex regimen of multiple medications.[1]
Spironolactone is an older, generic medication traditionally used as a potassium-sparing diuretic. It works by blocking aldosterone, a hormone that prompts the kidneys to retain sodium and water, thereby reducing overall fluid volume and lowering blood pressure.[1]
In the REDUCE trial, researchers enrolled 160 stroke survivors with uncontrolled hypertension across five medical centers in the United States. Participants were randomly assigned to receive either daily spironolactone or usual post-stroke care.[1]
After three months, patients taking the diuretic saw their home-measured systolic blood pressure drop by an average of 7.7 mm Hg more than the standard care group. The medication brought the average systolic reading down to 125.6 mm Hg.[1]
"We were surprised to see that blood pressure dropped twice as much as we expected," said Dr. Jordana B. Cohen, the lead researcher for the REDUCE trial. She noted that the effect was even stronger for patients who started the medication within 90 days of their stroke.[1]
More than half of the patients receiving spironolactone successfully reached a blood pressure target below 130/80 mm Hg. In contrast, only 30 percent of the participants assigned to standard care managed to achieve that same benchmark.[1]
Balancing benefits and safety
The push for lower blood pressure is not without its complications, and both trials highlighted the need for careful clinical oversight. Intensive blood pressure management requires a tailored approach rather than a blanket prescription.[2][5]
In the OPTIMAL-STROKE trial, the overall rate of serious adverse events was similar between the two groups, hovering around 15 percent. However, patients in the intensive treatment arm experienced a higher rate of kidney-related complications.[2][5]
The composite renal outcome, which included a sustained 50 percent drop in estimated glomerular filtration rate, occurred in 3.9 percent of the intensive group versus 2.2 percent of the standard group. This underscores the necessity of routine kidney function monitoring.[2][5]
"Achieving lower blood pressure safely requires appropriate medical supervision and additional monitoring, particularly of kidney function," Dr. Sampaio Silva cautioned. The intervention relies on close collaboration between the patient and their care team.[2]
Similarly, the REDUCE trial found that while spironolactone was generally well-tolerated, it carries specific risks. The medication can cause hyperkalemia, an elevation in blood potassium levels, which affected 4 percent of the treatment group.[1]
None of the elevated potassium cases in the REDUCE trial led to life-threatening complications, but the risk dictates regular blood tests. Patients taking aldosterone antagonists must have their electrolytes checked periodically to ensure their levels remain stable.[1]
Translating research into routine care
For stroke survivors, these findings offer a practical and reassuring framework for secondary prevention. The data confirms that aggressive blood pressure management is worth the effort, provided it is done under medical supervision.[4]
Patients currently recovering from an ischemic event should discuss their specific blood pressure targets with their neurologist or primary care physician. A target that was considered adequate five years ago may no longer represent the optimal standard of care.[4]
If a patient's blood pressure remains stubbornly high despite their current medication regimen, spironolactone represents a viable, inexpensive addition. Its generic status means it is widely accessible and unlikely to create a financial burden for patients.[1]
The integration of home blood pressure monitoring is another crucial takeaway from the recent data. The REDUCE trial relied heavily on digital home monitors, proving that patients can actively participate in tracking their own progress.[1]
Routine home monitoring provides a more accurate picture of a patient's true blood pressure than occasional clinic readings. It empowers survivors to take control of their recovery and provides physicians with the data they need to adjust dosages safely.[1]
Key points
- Driving systolic blood pressure below 120 mm Hg reduces the risk of major cardiovascular events by 21 percent in stroke survivors.
- The intensive blood pressure target lowered the specific rate of recurrent strokes from 6.4 percent to 4.7 percent over four years.
- Adding the low-cost diuretic spironolactone to a patient's regimen dropped home-measured systolic blood pressure by an average of 7.7 mm Hg.
- Intensive control requires routine monitoring, as patients face a higher risk of kidney function decline and elevated potassium levels.
What we don’t know
- Whether the addition of spironolactone directly translates to fewer recurrent strokes over a multi-year period, as the REDUCE trial was only powered to measure blood pressure reduction.
- How these intensive targets perform in patients with severe pre-existing kidney disease, as they were largely excluded from the trials.
- Whether the benefits of intensive blood pressure control apply equally to patients who suffered hemorrhagic strokes, since OPTIMAL-STROKE focused almost entirely on ischemic events.
How we got here
August 2019
The OPTIMAL-STROKE trial begins enrolling patients across 30 centers in Brazil to test intensive blood pressure targets.
April 2021
The REDUCE trial launches in the United States to evaluate spironolactone as a targeted therapy for uncontrolled post-stroke hypertension.
August 2022
Enrollment concludes for the OPTIMAL-STROKE trial, with researchers tracking patient outcomes for a median of nearly four years.
November 2026
Both trials present their findings at the American Heart Association Scientific Sessions, establishing new paradigms for secondary stroke prevention.
- Clinical Trial Investigators
- Argue that driving systolic blood pressure below 120 mm Hg provides superior cardiovascular protection and that low-cost tools like spironolactone make these targets achievable.
- Primary Care Physicians
- Emphasize the practical challenges of intensive blood pressure control, particularly the need for frequent laboratory monitoring to prevent kidney complications and electrolyte imbalances.
Perspectives this story doesn't cover
- Patients with severe pre-existing kidney disease, who were largely excluded from the trials.
Sources
[1]American Heart AssociationClinical Trial InvestigatorsCan a low-cost diuretic medication help to lower blood pressure after a stroke?
Read on American Heart Association →
[2]HCPLivePrimary Care PhysiciansAHA 2026: Intensive Blood Pressure Control Reduces Events After Ischemic Stroke
Read on HCPLive →
[3]TCTMDPrimary Care PhysiciansOPTIMAL-STROKE: Tight BP Control Pays Dividends After Ischemic Stroke or TIA
Read on TCTMD →
[4]American Heart AssociationClinical Trial InvestigatorsIntensive blood pressure control in stroke survivors lowered risk of cardiovascular events
Read on American Heart Association →
[5]New England Journal of MedicineClinical Trial InvestigatorsIntensive Blood-Pressure Control in Patients with Previous Ischemic Stroke
Read on New England Journal of Medicine →
[6]National Institutes of HealthClinical Trial InvestigatorsIntensive Blood-Pressure Control in Patients with Previous Ischemic Stroke
Read on National Institutes of Health →
More in Health
See all →Coronary Artery Disease
Early Invasive Heart Procedures Offer No Survival Advantage Over Medication in Stable Disease
5 sources
Deprescribing
Stopping Statins Safe for Older Adults Without Heart Disease, Trial Finds
5 sources
Human Biology
Irreversible Platelet COX-1 Inactivation: Why Low-Dose Aspirin Suppresses Clotting for Ten Days Despite a 20-Minute Plasma Half-Life
5 sources
FDA Decisions
FDA Rejects Capricor's Duchenne Cell Therapy, Citing Serious Data Integrity Violations
5 sources
Comments
Every angle. Every day.
Get Health stories with full source coverage and perspective breakdowns, free every day.




